Drug
Felzartamab clinical trials
Also written MOR202 and MOR03087.
- studies test it
- 16
- open now
- 5
- in phase 3
- 4
- first study started
- 2011
Keep track of what changes. Save the felzartamab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
16 studies that test it; most in 2021 (5)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2019 | 3 |
| 2021 | 5 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 10
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 2
Biogen (6) · HI-Bio, A Biogen Company (4) · TJ Biopharma Co., Ltd. (3) · Mario Negri Institute for Pharmacological Research (1) · Farsad Eskandary (1) · MorphoSys AG (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses felzartamab is read from its arms, and is right about nine times in ten.
Testing it · 16
- A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular InflammationRecruitingPhase 2BiogenNCT07219043Written as Felzartamab
- A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)Not yet recruitingPhase 2BiogenNCT07889362Written as Felzartamab
- A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years OldRecruitingPhase 2BiogenNCT07722546Written as Felzartamab
- A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)RecruitingPhase 3BiogenNCT06935357Written as Felzartamab
- A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)Enrolling by invitationPhase 3BiogenNCT07444489Written as Felzartamab
- A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years OldCompletedPhase 1HI-Bio, A Biogen CompanyNCT06064929Written as Felzartamab
- MOR202 for Refractory MNCompletedPhase 2Mario Negri Institute for Pharmacological ResearchNCT04893096Written as MOR202
- A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)Active, not recruitingPhase 3BiogenNCT06685757Written as Felzartamab
- Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA NephropathyCompletedPhase 2HI-Bio, A Biogen CompanyNCT05065970Written as Felzartamab
- TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedPhase 2TJ Biopharma Co., Ltd.NCT03860038Written as TJ202 and Dexamethasone
- Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)CompletedPhase 1/2HI-Bio, A Biogen CompanyNCT04145440Written as MOR202
- Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)CompletedPhase 2HI-Bio, A Biogen CompanyNCT04733040Written as MOR202
- TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedPhase 3TJ Biopharma Co., Ltd.NCT03952091Written as TJ202, Lenalidomide and Dexamethasone
- Felzartamab in Late Antibody-Mediated RejectionCompletedPhase 2Farsad EskandaryNCT05021484Written as Felzartamab
- A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus ErythematosusTerminatedPhase 1TJ Biopharma Co., Ltd.NCT05140824Written as TJ202 injection
- A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple MyelomaCompletedPhase 1/2MorphoSys AGNCT01421186Written as MOR03087 phase 1 dose escalation
Given in every arm · 1 — felzartamab is usual care beside what is tested
Codes
What other systems call felzartamab · ClinicalTrials.gg INT001384
- MeSH (NLM) C000709267felzartamabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 3O9FA4XC02FELZARTAMABConfirmed FDA, NLM
- NCI Thesaurus C97954FelzartamabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000709267 | felzartamab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 3O9FA4XC02 | FELZARTAMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C97954 | Felzartamab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.